Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 6/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22705350 | 0.90 | GPR6 (0.42) | RIPK1ARGPR6SCDSCD5 | |
| SCHEMBL24597731 | 0.88 | SMN1; SMN2 (0.43) | RIPK1ARGPR6SCDSMN1; SMN2 | |
| SCHEMBL22705508 | 0.87 | RIPK1 (0.56) | RIPK1SCDSCD5SMN1; SMN2ADAM17 | |
| SCHEMBL22705380 | 0.87 | RIPK1 (0.56) | RIPK1SCDSCD5SMN1; SMN2ADAM17 | |
| SCHEMBL22705348 | 0.86 | RIPK1 (0.50) | RIPK1SCDSCD5SMN1; SMN2ROCK2 | |
| SCHEMBL22705456 | 0.85 | L3MBTL1 (0.48) | RIPK1SCDSCD5SMN1; SMN2ROCK2 | |
| SCHEMBL22705446 | 0.83 | RIPK1 (0.47) | RIPK1SCDSCD5SMN1; SMN2ROCK2 | |
| SCHEMBL22705445 | 0.83 | RIPK1 (0.50) | RIPK1SCDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL22688972 | 0.82 | RIPK1 (0.44) | RIPK1SCDSCD5SMN1; SMN2ROCK2 | |
| SCHEMBL22688971 | 0.82 | RIPK1 (0.44) | RIPK1SCDSCD5SMN1; SMN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213077-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-07-07 | — | — | US | disclosed |
| WO-2020233618-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 (CN) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213077-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | LITAF, TNF, BAD | RIPK1 146/4885AR 4700/4885GPR6 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.